ClinicalTrials.gg
CompletedNCT06122714Updated Dec 13, 2024

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

A Phase 1 interventional study of AZD4144 Part A and AZD4144 Part B in Healthy Participants, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.

Read the detailed description

This is a Phase I, first time-in human (FTiH), randomised, single-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) sequential group study in healthy participants.

Part A consists of 3 parts:

Part A1 (healthy participants) Part A2 (healthy Japanese participants) and Part A3 (healthy Chinese participants)

Part B consists of 2 parts:

Part B1 (healthy participants) Part B2 (healthy Japanese participants)

Both Part A and Part B of the study will comprise of a screening period of maximum 28 days. The treatment period would last from Day -1 to Day 4 in Part A and from Day -1 to Day 15 in Part B of the study. A follow up visit will be performed on Day 10 + 3 days for Part A and on Day 20 + 3 days for Part B.

Each participant will participate for about 6 weeks in Part A of the study and for about 7 weeks in Part B of the study.

02

Conditions studied

  • Healthy Participants

Keywords

  • Single ascending dose (SAD)
  • Multiple ascending dose (MAD)
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must have a negative pregnancy test, must not be lactating and must be of non-.
  • Have a between 18 and 32 kg/m2 inclusive at both Screening and Admission and weigh at least 45 kg at Screening.
  • For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female (of non-childbearing potential) participants are to be Japanese, defined as having both parents and four grandparents who are Japanese. This included second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • For healthy Chinese cohort (Part A3): healthy male and female (of non-childbearing potential) Chinese participants for whom both parents and all grandparents are Chinese and not lived outside of China for more than 10 years.

Exclusion criteria

Exclusion criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study.
  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure or trauma.
  • Clinically significant serious active and chronic infections.
  • Bacillus Calmette-Guérin vaccine within one year prior to signing the ICF.
  • Any abnormal laboratory values at the Screening Visit.
  • Any positive result on Screening for serum surface antigen (HBsAg), anti-Hepatitis B core (HBc), antibody, or (HIV).
  • Any cardiac abnormalities.
  • History of alcohol abuse or drug abuse.
  • Current smokers or those who have smoked or used nicotine products.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Clinical signs and symptoms consistent with COVID-19.
  • In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

    1. Previous bone marrow transplant
    2. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Part A1 (healthy participants) Cohort 1

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A1 (healthy participants) Cohort 2

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A1 (healthy participants) Cohort 3

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A1 (healthy participants) Cohort 4

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A1 (healthy participants) Cohort 5

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A1 (healthy participants) Cohort 6

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Placebo comparator
    Part A1 (healthy participants) placebo

    Participants will receive matching Placebo.

    Drug: Placebo Part A

  • Experimental
    Part A2 (healthy Japanese participants) Cohort 1

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Experimental
    Part A2 (healthy Japanese participants) Cohort 2

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Placebo comparator
    Part A2 (healthy Japanese participants) placebo

    Participants will receive matching placebo.

    Drug: Placebo Part A

  • Experimental
    Part A3 (healthy Chinese participants) Cohort 1

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144 Part A

  • Placebo comparator
    Part A3 (healthy Chinese participants) placebo

    Participants will receive matching placebo.

    Drug: Placebo Part A

  • Experimental
    Part B1 (healthy participants) Cohort 1

    Participants will receive one multiple ascending dose of AZD4144.

    Drug: AZD4144 Part B

  • Experimental
    Part B1 (healthy participants) Cohort 2

    Participants will receive one multiple ascending dose of AZD4144.

    Drug: AZD4144 Part B

  • Experimental
    Part B1 (healthy participants) Cohort 3

    Participants will receive one multiple ascending dose of AZD4144.

    Drug: AZD4144 Part B

  • Placebo comparator
    Part B1 (healthy participants) placebo

    Participants will receive matching placebo.

    Drug: Placebo Part B

  • Experimental
    Part B2 (healthy Japanese participants) Cohort 1

    Participants will receive one multiple ascending dose of AZD4144.

    Drug: AZD4144 Part B

  • Placebo comparator
    Part B2 (healthy Japanese participants) placebo

    Participants will receive matching placebo.

    Drug: Placebo Part B

Interventions

  • Part A: Participants will be administered a single oral dose on Day 1.

  • Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.

  • DrugPlacebo Part A

    Part A: Participants will be administered a single oral dose of matching placebo on Day 1.

  • DrugPlacebo Part B

    Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of AZD4144 following oral administration of single and multiple ascending doses (Part A and Part B)

    Time frame: Part A: From screening (Day -28 to Day -2) to Day 10; Part B: From screening (Day -28 to Day-2) to Day 20

Secondary outcomes

  1. Maximum observed plasma (peak) drug concentration (Cmax)

    To characterise the single dose and steady state PK of AZD4144 following oral administration of single and multiple ascending doses (Part A and Part B).

    Time frame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20

  2. Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

    To characterise the single dose and steady state PK of AZD4144 following oral administration of single and multiple ascending doses (Part A and Part B)

    Time frame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20

  3. Area under plasma concentration-time curve from zero to infinity (AUC0-inf)

    To characterise the single dose and steady state PK of AZD4144 following oral administration of single and multiple ascending doses (Part A and Part B)

    Time frame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20

  4. Renal clearance of drug from plasma (CLR)

    To characterise the single dose and steady state PK of AZD4144 following oral administration of single and multiple ascending doses (Part A and Part B)

    Time frame: Part A: Day 1 to Day 4. and Day 10; Part B: Day 1 to Day 15 and Day 20

  5. PD analysis: Levels of disease-specific biomarkers

    To assess the effect of AZD4144 on levels of disease-specific biomarkers.

    Time frame: Part A: Day 1 to Day 4 and Day 10; Part B: Day -1, Day 1 to Day 4, Day 12 to Day 15 and Day 20

07

Study locations

2 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Nov 7, 2023
Primary completionActual
Dec 4, 2024
CompletionActual
Dec 4, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122714
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Nov 7, 2023
Primary completion
Dec 4, 2024
Completion
Dec 4, 2024
Last update
Dec 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD4144

Start the discussion